Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 55 of 117 for:    Atenolol

To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable,Symptomatic Chronic Angina

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02623569
Recruitment Status : Unknown
Verified December 2015 by Xintong Pharmacy Company.
Recruitment status was:  Recruiting
First Posted : December 7, 2015
Last Update Posted : December 7, 2015
Information provided by (Responsible Party):
Xintong Pharmacy Company

Brief Summary:

Arms Assigned Interventions

Experimental: Ivabradine Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR>60times/min or negative ETT and HR>80times/min of subjects.

Active Comparator: Atenolol Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and heard rate>60times/min or negative ETT and HR >80times/min of subjects.

Condition or disease Intervention/treatment Phase
Angina Pectoris Drug: Ivabradine Drug: Atenolol Phase 2

Detailed Description:
  1. Washout period:Chronic angina patients stop using medicine that affect heart rate. The patients undergoes ETT after 2-7 days and positive ETT into the treatment period(If not take similar medicine, patients can be carried out ETT directly)。
  2. Treatment period:Patients carried out ETT after therapy with Ivabradine(5mg,bid)/ Atenolol(12.5mg,bid) for 4 weeks.The dose adjust base on test result and heart rate, Ivabradine(5mg,bid)/Atenolol(12.5mg,bid) or Ivabradine(7.5mg,bid)/ Atenolol(25mg,bid) for 8 weeks and carried out ETT.
  3. security period:After the treatment period, all patients to take Atenolol 12.5mg/ 25mg bid 1 week.

If heart rate are low 50 times/min after taking Ivabradine 5mg/ Atenolol 12.5mg, subjects should withdrawal and dropped out study. If subjects heart rate are low 50 times/min after taking Ivabradine 7.5mg/ Atenolol 25mg, subjects should change the dose to Ivabradine 5mg/ Atenolol 12.5mg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 336 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study
Study Start Date : October 2014
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Arm Intervention/treatment
Experimental: Ivabradine
Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR(heard rate)>60times/min or negative ETT and HR(heard rate)>80times/min of subjects.
Drug: Ivabradine
Not Provided
Other Name: Not Provided

Active Comparator: Atenolol
Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR(heard rate)>60times/min or negative ETT and HR (heard rate)>80times/min of subjects.
Drug: Atenolol
Not Provided
Other Name: Not Provided

Primary Outcome Measures :
  1. The primary efficacy endpoint is Change from total exercise duration in exercise tolerance test (ETT) [ Time Frame: Baseline and end of treatment (Week 12) . ]

Secondary Outcome Measures :
  1. Time to angina in exercise tolerance test. [ Time Frame: 12 weeks ]
  2. Time to 1 mm ST-segment depression in exercise tolerance test [ Time Frame: 12 weeks ]
  3. Number of angina attacks in exercise tolerance test per week [ Time Frame: 12 weeks ]
  4. Number of sublingual nitroglycerin consumption per week [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. male or female aged 18 to 75 years
  2. Clearly understand the study and participate in it voluntarily; the informed consent should be signed in person or by legal guardian.
  3. Chronic Stable Angina was confirmed by clinic over 3 months.
  4. Patients with clinical diagnosis of chronic stable angina and must meet one of the following conditions:

    • Patients who have a history of myocardial infarction over 3 months.
    • Patients who have received coronary intervention or CABG(Coronary Artery Bypass Grafting) over 6 months.
    • Stenosis of more than 50% in at least one major epicardial coronary artery shown by Coronary Angiograph.
    • Ischemic electrocardiogram changes:ST-segment depression ≥ 1.0 mm compared with P-R or elevate≥1.0 mm during exercise ECG Computed Tomography Angiography (CTA) showed more than 50% stenosis with typical angina symptoms
  5. ultrasonic cardiogram disclosed that left ventricular ejection fraction ≥50 %.
  6. Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) at screening.

Exclusion Criteria:

  1. Clinically significant Valvular disease, congenital heart disease, pulmonary hypertension, cerebral apoplexy, dissecting aneurysm, hypertrophic cardiomyopathy, acute myocarditis/cp.
  2. Patients with myocardial infarction within the preceding 3 months
  3. Patients have received Coronary angioplasty or CABG within the preceding 6 months.
  4. Patients who have severity vessels disease with left main coronary artery but have no valid treatment.
  5. Patients with congestive heart failure(New York Heart Association class III or IV)or acute pulmonary edema.
  6. Patients whose rest heart rate< 60 bpm.
  7. Patients with nonrespiratory sinus arrhythmia or arrhythmia(e.g.,AVB(auriculo-ventricular block)ⅡⅢ,atrial fibrillation,atrial flutter,SSS(sick sinus syndrome)) or implantable cardiac defibrillator (ICD).
  8. Patient with any conditions that interfered the performance of exercise tolerance test or a history of an abnormal exercise response limited by electrocardiograph (ECG) changes.
  9. Patient with uncontrolled hypertension (seated systolic blood pressure (SBP)≥180 mmHg or diastolic blood pressure (DBP) ≥100 mmHg); SBP<90 mmHg and/or DBP<60 mmHg
  10. Diabetic with uncontrolled blood glucose(FBG≥11.1 mmol/L and/or RBG≥13.6 mmol/L)
  11. Patients with anemia(male:Hb≤120 g/L;female:Hb≤110 g/L)
  12. Patients complicated with systemic diseases included thyroid dysfunction、glaucoma、cataract,neurological、mental、psychological disease and any other disease that influence the judgment.
  13. Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).
  14. Patients with mental or legal disorder.
  15. Patients who were suspected addicted into alcohol or drug abuse or with severe complications that would make the condition more complicated assessed by the investigator.
  16. People have liver or renal dysfunction (ALT≥2×ULN、AST≥2×ULN、eGFR≤60ml/min/1.73m2)
  17. Patients who should use unapproved drug during the study.
  18. Patients who accepted amiodarone(in recent 3 months)and/or benzetimide、βblockers(in recent 7 days)、
  19. Patients with history of allergy or suspected allergic to the drug(e.g.,Hydrochloric ivabradine,atenolol, βblockers)or lactose.
  20. Woman who disagree with contraception during treatment period ,with pregnancy, lactation or positive result of pregnancy test.
  21. Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators.
  22. Patients who is participating in other trials or has been participated in other trials in recent 3 months
  23. Patients who were unable to participate in the study as judged by investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02623569

Layout table for location information
China, Guizhou
Guizhou Provincial People's Hospital Recruiting
Guiyang, Guizhou, China, 550001
Contact: Ping Zhang    0851-5623033   
China, Jiangsu
Zhongda Hospital Southeast University Recruiting
Nanjing, Jiangsu, China, 210009
Contact: Genshan Ma    025-83272038   
China, Liaoning
The General Hospital of Shenyang Military Recruiting
Shenyang, Liaoning, China, 110016
Contact: Yaling Han    024-28897309   
Sponsors and Collaborators
Xintong Pharmacy Company

Layout table for additonal information
Responsible Party: Xintong Pharmacy Company Identifier: NCT02623569    
Other Study ID Numbers: A130901CSPF01
First Posted: December 7, 2015    Key Record Dates
Last Update Posted: December 7, 2015
Last Verified: December 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations
Signs and Symptoms
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action